Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $15.3333.

Several equities analysts recently issued reports on the company. Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th. Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday, August 12th. Finally, Roth Capital began coverage on shares of Coya Therapeutics in a research report on Friday, June 5th. They issued a “buy” rating and a $12.00 price target on the stock.

Coya Therapeutics Stock Down 2.2%

Shares of NASDAQ COYA opened at $4.86 on Friday. The stock’s 50 day moving average price is $4.89 and its two-hundred day moving average price is $4.67. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75. The stock has a market capitalization of $114.02 million, a P/E ratio of -4.54 and a beta of 0.60.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. On average, analysts anticipate that Coya Therapeutics will post -1.44 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Large investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. acquired a new position in Coya Therapeutics in the fourth quarter valued at approximately $4,640,000. AWM Investment Company Inc. acquired a new stake in shares of Coya Therapeutics during the 4th quarter worth approximately $4,205,000. CM Management LLC raised its position in shares of Coya Therapeutics by 16.7% during the 4th quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after purchasing an additional 50,000 shares during the period. Private Management Group Inc. bought a new stake in shares of Coya Therapeutics in the 4th quarter worth approximately $1,626,000. Finally, Marshall Wace LLP lifted its holdings in shares of Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after purchasing an additional 183,533 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.